Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
Stock Information for Tiziana Life Sciences Ltd
Loading
Please wait while we load your information from QuoteMedia.